Compare Marex Group Limited Ordinary Shares (MRX) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Marex Group Limited Ordinary Shares vs Natera Inc. Common Stock — how do they compare? Marex Group Limited Ordinary Shares trades at $68.92 (market cap $5.18B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 11× Marex Group Limited Ordinary Shares's market cap, and Marex Group Limited Ordinary Shares pays a 0.89% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Marex Group Limited Ordinary Shares for 3 Days and Natera Inc. Common Stock for 0 Days on average.
| MRX | NTRA | |
|---|---|---|
Market Cap | $5.18B | $57.03B |
Volume | 794,309 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $78.27 | $425.64 |
52-Week Low | $29.92 | $179.42 |
Typical Hold Time | 3 Days | 0 Days |
Enterprise Value | $8.26B | $56.18B |
Dividend Yield | 0.89% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRX trades at $71.95, down 0.47% on the day, with a neutral technical signal despite bullish moving averages. The company demonstrates strong fundamentals with a P/E of 14.62 and robust profitability, including a 9.69% net income margin and 27.57% ROE. Recent quarterly earnings have consistently beaten expectations, with Q2 2026 EPS of $1.64 surpassing the $1.36 estimate. Positive news includes record H1 2026 results and strategic developments in financial infrastructure.
The outlook for MRX is positive, supported by strong earnings momentum, a 100% buy rating from analysts, and a consensus price target of $83.67 implying significant upside. Key risks include execution of its acquisition strategy and market volatility. The stock's current valuation and growth trajectory present a compelling opportunity, though investors should monitor debt levels and competitive pressures.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Marex Group Limited Ordinary Shares
Marex Group provides financial services across commodities, financial markets, and corporate clients. Its services include clearing, agency and execution, market making, hedging, and securities services.
Read more on MRX →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
